A new partnership between BioMotiv and Bristol-Myers Squibb (BMS) will see both parties develop new innovative therapies for patients that need the most.
Under the terms of the strategic partnership, BMS will become a limited partner of BioMotiv with the option to invest additional funding in selected projects of mutual interest.
Both parties will form and fund new companies to develop novel therapeutics in disease areas where unmet medical needs remain.
Upon the identification of a preclinical candidate molecule, BMS will have the option to acquire the company from BioMotiv under pre-agreed terms.
“This new partnership effectively pairs two organisations with a mission – to translate transformational discoveries into breakthrough therapies for patients living with serious diseases,” said Satish Jindal, BioMotiv’s Managing Director.